BioNTech SE (BNTX) Profit After Tax (2018 - 2025)
BioNTech SE (BNTX) posted Profit After Tax of -$355.0 million for Q4 2025, down 958.16% sequentially from -$33.6 million in Q3 2025, and down 228.03% YoY from $277.3 million in Q4 2024.
BioNTech SE (BNTX) Profit After Tax (2018 - 2025) Analysis & Trends
BioNTech SE has reported Profit After Tax for 8 years, with the latest figure at -$355.0 million in Q4 2025.
- Quarterly Profit After Tax fell 228.03% year-over-year to -$355.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.3 billion (down 76.14% YoY) and the FY2025 annual result came in at -$1.3 billion, down 80.55% from the prior year.
- Profit After Tax eased to -$355.0 million in Q4 2025 per BNTX's latest filing, from -$33.6 million in the prior quarter.
- Over five years, Profit After Tax peaked at $4.2 billion in Q1 2022 and troughed at -$869.9 million in Q2 2024.
- A 5-year average of $1.1 billion and a median of $385.0 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2021 and 2024: Profit After Tax soared 827987404.69% in 2021, then sank 319.57% in 2024.
- Over 5 years, Profit After Tax stood at $3.6 billion in 2021, then slumped by 35.81% to $2.3 billion in 2022, then plunged by 78.81% to $492.7 million in 2023, then sank by 43.72% to $277.3 million in 2024, then plunged by 228.03% to -$355.0 million in 2025.
- According to Business Quant data, Profit After Tax over the past three periods registered -$355.0 million, -$33.6 million, and -$437.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -355.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -355.03 Mn |
| Sep 30, 2025 | -33.55 Mn |
| Jun 30, 2025 | -437.62 Mn |
| Mar 31, 2025 | -437.37 Mn |
| Dec 31, 2024 | 277.30 Mn |
| Sep 30, 2024 | 217.56 Mn |
| Jun 30, 2024 | -869.91 Mn |
| Mar 31, 2024 | -342.31 Mn |
| Dec 31, 2023 | 492.67 Mn |
| Sep 30, 2023 | 174.83 Mn |
| Jun 30, 2023 | -207.33 Mn |
| Mar 31, 2023 | 539.03 Mn |
| Dec 31, 2022 | 2.32 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.78 Bn |
| Mar 31, 2022 | 4.15 Bn |
| Dec 31, 2021 | 3.62 Bn |
| Sep 30, 2021 | 3.79 Bn |
| Jun 30, 2021 | 3.36 Bn |
| Mar 31, 2021 | 1.36 Bn |